Note: Ingredients listed on restricted chemical lists
EC/CAS
231-722-6/7704-34-9
Name of the chemical
sulphur
Concentration
10 - 20
EC/CAS
203-473-3/107-21-1
Name of the chemical
Ethane-1,2-diol
Concentration
0.15 - 0.2
EC/CAS
220-120-9/2634-33-5
Name of the chemical
1,2-Benzisothiazol-3(2H)-one
Concentration
<0.01
EC/CAS
220-239-6/2682-20-4
Name of the chemical
2-Methyl-2H-isothiazol-3-one
Concentration
<0.01
General Information
Version
3.0
Revision date
2022-10-21
Product name
SOLFOUREA PALLARÉS LIQUID PLUS
1.2.1 Relevant identified uses
Industrial/Professional use spec
Emergency telephone
+34 977 524 650
Icons in SDS
Company Information
company name
AZUFRERA Y FERTILIZANTES PALLARES, S.A.U
e-mail address of the competent person responsible for the Safety Data Sheet
afepasa@afepasa.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H317
Hazard statements
Code
Statements
H315
Causes skin irritation
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Causes skin irritation. May cause an allergic skin reaction.
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Contains
1,2-benzisothiazol-3(2H)-one, 2-methylisothiazol-3(2H)-one
Hazard statements
H315 - Causes skin irritation. H317 - May cause an allergic skin reaction.
Precautionary statements
P261 - Avoid breathing vapours. P264 - Wash hands, forearms and face thoroughly after handling. P272 - Contaminated work clothing should not be allowed out of the workplace. P280 - Wear protective gloves. P302+P352 - IF ON SKIN: Wash with plenty of water and soap. P333+P313 - If skin irritation or rash occurs: Get medical advice/attention.
PBT Substances
not yet assessed
vPvB Substances
not yet assessed Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %